Navigation Links
Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement
Date:8/10/2009

    NASDAQ: CRME   TSX: COM

VANCOUVER and DEERFIELD, IL, Aug. 10 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

The decision to conduct another trial was reached following extended discussions with the FDA to define the best regulatory path forward for KYNAPID. Under the Special Protocol Assessment (SPA) process, the FDA has agreed that the design and planned analysis of the study adequately address objectives in support of the KYNAPID New Drug Application (NDA). The prospectively-defined trial will enroll recent-onset atrial fibrillation patients without a history of heart failure. Cardiome and Astellas believe that this study, coupled with the overall clinical development program, should in principle meet the FDA standards for approval.

"In addition to receiving a positive recommendation for approval from the FDA Cardiovascular and Renal Drugs Advisory Committee, KYNAPID has demonstrated consistent results across all of the four completed Phase 3 clinical trials," said William E. Fitzsimmons, PharmD, Senior Vice President, Development at Astellas. "We are confident that the ACT 5 trial will confirm these prior results and further demonstrate the therapeutic value of this exciting drug candidate."

"We support the decision to conduct the ACT 5 trial, and we will assist our partner Astellas in every way to expedite the launch and successful completion of this study," said Doug Janzen, President and Chief Executive Officer of Cardiome. "We estimate that Cardiome's alloca
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. aTyr Pharma Raises an Additional $12 Million
2. Texas Kidney Community: CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities, Creating More Local Jobs
3. SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia
4. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
5. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
6. Specialty Hospitals of Washington Adds Additional Skilled Nursing Facility Beds at United Medical Center in South East DC
7. King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan
8. Visit to the doctor: The supply of additional private services is increasing
9. Business, Health Care Leaders Call on Texas Employers to Cover Smoking Cessation Benefits for an Additional 100,000 People by 2010
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. New Jersey University Hospital to Pay Additional $2 Million to Resolve Fraud Claims That Facility Double Billed Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... September 02, 2014 Renal cell carcinoma (RCC) ... lining of the proximal convoluted tubule, a part of the ... from the blood to the urine. The condition is asymptomatic ... RCC are often in the advanced stages of the disease ... RCC often include blood in the urine, flank pain, a ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... explain why C-section babies seem more likely to develop ... (HealthDay News) -- Babies who are born vaginally pick ... cesarean section, potentially affecting how their immune systems develop, ... provide more insight into why babies born through cesarean ...
... the polycystic ovary syndrome (PCOS), the most common hormone imbalance ... exposure to the chemical bisphenol A (BPA), found in many ... will be presented Sunday at The Endocrine Society,s 92nd Annual ... a known hormone disrupter, is elevated and associated with higher ...
... ... and revenues. In this Social Media Zuberance webinar we will show you how to avoid becoming ... ... (Founder and CEO of Zuberance) for a free interactive webinar at 11 AM PDT/2 ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... to Doctors, Physicians and Health Care Providers will monetize their time and streamline their patient ... the next sixty days. , ... (PRWEB) June 21, 2010 -- DocGreet.com is so sure that the services available to ...
... mental disorder affecting one in 100 people worldwide. Most cases ... and hallucinations as a teenager or adult. By that time, ... be difficult to treat. In a paper published recently ... at the University of North Carolina at Chapel Hill and ...
Cached Medicine News:Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:Women with polycystic ovary syndrome have higher BPA blood levels 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Brain signs of schizophrenia found in babies 2
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... ... , LONDON, Dec. 14 A new solution developed by IBM ... Malaria Partnership, is helping to save lives using everyday technology to ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091214/NY25146-a ) , (Photo: ...
... , GENEVA, Switzerland, December 14 ... Meeting was held,in Bermuda on 7th December. In excess of ... and overwhelmingly approved all the resolutions,put forward. , ... Shortt of Galmoy,as the new Director of Corporate Communications. In ...
Cached Medicine Technology:Saving Lives with SMS for Life 2Saving Lives with SMS for Life 3Saving Lives with SMS for Life 4Saving Lives with SMS for Life 5Calcitech Holds Annual General Meeting 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
... The BacT/Alert 3D Select is ... automated microbial detection system that ... and mycobacteria culturing. This system ... management or laboratory information system ...
Medicine Products: